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Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road,
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Summary In order to assess the importance of the intensity of administration of chemotherapy in the
management of advanced germ cell tumours we have calculated indices of chemotherapy. These have been
used to compare the treatment given to patients who subsequently relapsed with matched controls who did
not relapse. Two of these indices (alpha and beta) are derived from the doses of drugs whose dose is varied
(cisplatinum, methotrexate and etoposide). These indices showed significant variation between cases and
controls. Indices gamma and delta are derived from drugs whose dose is not varied. They showed no
significant differences between the two groups. These results emphasise the importance of ensuring that
patients with these curable cancers receive adequate doses of chemotherapy.
Germ cell tumours are responsive to cytotoxic drugs to the
extent that the majority of patients with metastatic disease
enter long-term complete remission after treatment with
combination chemotherapy. There are several regimens for
such treatment but all of those in current use contain cis-
platin. Other frequently used drugs include bleomycin, eto-
poside (VP16-213) and the vinca alkaloids. It is a matter of
some debate how intense such treatment should be to obtain
optimum results. Einhorn (1986) has argued that the appar-
ent superiority over standard regimens of those with
increased intensity is erroneous and simply reflects a general
improvement in the quality of care of these patients.
While the ideal method by which the importance of
intensity of treatment regimens might be assessed is in a
prospective randomised trial, it is possible to identify varia-
tions in the chemotherapy actually administered to patients
within one study. At this hospital a combination of cis-
platin, vincristine (Oncovin), methotrexate and bleomycin
(POMB) alternating with actinomycin D, cyclophosphamide
and etoposide (ACE) has been in use in its present form since
1979. It is associated with long-term survival rates of greater
than 90% (Newlands et al., 1986). The purpose of this
analysis is to assess the intensity of treatment in those
patients who have eventually relapsed and compare it with
those who remain in remission. POMB/ACE chemotherapy
is highly individualised both in its duration and in the
quantity of drugs used. In order to make the comparison it
is therefore necessary to use a matched pair analysis.
Patients and methods
The patients studied were those who had received their
initial chemotherapy at Charing Cross Hospital using the
POMB/ACE regimen. Experience between 1977 and 1979
showed that when using this treatment with only two POMB
courses the most significant prognostic factor is the serum
concentration of chorionic gonadotrophin (hCG) and of
alpha fetoprotein (AFP) at the time treatment is started
(Newlands et al., 1983). When these parameters are taken
into account, conventional measures of extent of disease are
not significantly related to prognosis. It has been shown
that, in the United Kingdom, there has been a consistent
improvement in the results of treatment of these patients
over the past decade (Medical Research Council, 1985). This
is also reflected in the reduction of the prognostic signifi-
cance of AFP and hCG seen in the Charing Cross series
with the increase in POMB courses since 1979 to at least
three (Newlands et al., 1986). In this study, therefore, each
patient who relapsed was paired with a control who had
similar values for tumour markers and who was treated as
near contemporaneously as possible to the relapsed patient.
When both hCG and AFP were elevated, the higher marker
was used for matching. The control was required to have
been treated within a year before or after the patient who
relapsed. This time parameter automatically ensured the
selection of the control for each subject. A comparison of
the disease sites is shown in Table I.
Indices of chemotherapy were calculated to quantify the
amount of cytotoxic drugs received by the patients. In the
POMB/ACE regimen both the total dose of cisplatinum (see
below) and the duration of chemotherapy are adjusted
according to the patient's tumour; treatment continues until
tumour markers have been normal for three months.
Chemotherapy was therefore analysed in respect of two
separate periods: the first four months of treatment, when
most or all of the cisplatinum is given, and the subsequent
treatment (Figure 1).
Three of the drugs in the regimen are varied in dosage.
Cisplatin is given until marker concentrations are within
acceptable limits with a minimum of three courses being
employed. In the ACE course, etoposide is normally given
daily for 5 days but when myelosuppression is severe the
duration may be reduced to 4 or 3 days. The dose of
methotrexate is escalated from 300 to 1,000mgm-2 (with
increased folinic acid rescue) for patients with brain meta-
stases. The doses of bleomycin, vincristine, actinomycin D
and cyclophosphamide are not deliberately adjusted, the
quantity received by a patient depending on the frequency of
administration and the duration of treatment.
Indices of chemotherapy were calculated which apply to
the first four months of treatment as follows: standard
treatment within that period is taken to consist of POMB-
POMB-ACE-POMB-ACE-POMB-ACE-OMB. The index
Table I Comparison of cases who relapsed and controls who did
not, by site of disease
Case Control
Case and Case and positive, positive,
control control control case
Site positive negative negative negative
Para-aortic 7 3 5 2
Lung 7 5 2 3
Liver 2 9 3 3
Brain 2 14 0 1
Mediastinum 1 12 2 2
Female pelvis 3 13 0 1
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Figure 1 Stylised representation of standard POMB/ACE chemotherapy.
alpha describes the drugs showing greatest variation. The
denominator in each term is the quantity of drug per m2
administered in the standard treatment. The numerator is the
amount per m2 actually given.
alpha =(S/480 +M/I ,500 +El1,500)/3
where S is the amount of cisplatin, M is the amount of
methotrexate and E is the amount of etoposide. This index
has very high values in patients being treated for brain
metastases due to the escalated dose of methotrexate
employed. It has values of less than 1 in patients with
tumour marker levels which are normal or return to normal
before the fourth POMB is due. Index gamma describes the
other drugs.
gamma =(O/5 +B/i150 +A/4.5 +C/1,500)/4
where 0 is the amount of vincristine (Oncovin), B is that of
bleomycin, A is that of actinomycin D and C is that of
cyclophosphamide.
The denominators in the derivation of the indices for
subsequent treatment were arbitrarily derived from the mean
quantity per m2 received by the patients in the control
group, excluding those receiving escalated dose methotrexate.
The patients with brain metastases therefore have high
values of beta.
beta =(S/68 +M/390+E/820)/3
delta =(O/1.8 +B/54+A/1.8 + C/867)/4
The values for these indices were compared in cases and
controls using Student's t test for paired observations. This
analysis was employed because the heterogeneity of POMB/
ACE treatment demands comparisons between matched indi-
viduals rather than groups.
Results
There were 17 pairs of patients. The two groups were shown
to be well matched for tumour marker values at the start of
treatment. While there was some variation between those
who relapsed and controls in respect of hCG and AFP
(Figure 2) this was random and not statistically significant
(t test for paired observations). When patients are compared
by the higher marker in each pair, the values show little
variation. There were no differences between sites of disease
between the groups that might account for the different
outcome (Table I).
One pair was unevaluable for index alpha because one
member (the control) had a cerebral metastasis and was
therefore prescribed the higher dose of methotrexate. All
other pairs were concordant for the presence or absence of
cerebral metastases and the comparison was therefore valid.
In four pairs the treatment of both members did not extend
beyond 4 months so they contribute no data to indices beta
and delta.
The comparison of the indices in the cases and controls is
shown in Figure 3. Alpha was significantly greater in the
controls (t=2.742, d.f. = 15, P=0.015) as was beta (t=2.292,
d.f.=1, P=0.041). The comparisons for gamma (t= 1.003,
d.f. = 16, P=0.333) and delta (t= 1.089, d.f. = 12, P=0.298)
showed no significant difference.
The cause of the reduced treatment intensity in most of
the patients who relapsed was myelosuppression, which
caused treatment delays and resulted in a reduced dose of
etoposide being employed.
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Figure 2 Comparison of hCG, AFP and the higher of the
markers in the two groups of patients.
Discussion
It has been proposed that the dose of cytotoxic agents is
important in determining the outcome of treatment (Frei &
Canellos, 1980). This does not necessarily demand the
approach of giving large doses on each occasion that
treatment is administered; Carde et al. (1983) have shown
that the method of administration of MOPP chemotherapy
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Figure 3 Comparison of the indices of treatment alpha, beta,
gamma and delta between the two groups of patients.
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has a bearing on the outcome of Hodgkin's disease, the rate
of drug delivery being the variable most strongly associated
with the attainment of complete response.
The most detailed studies of dose intensity in cancer
chemotherapy have been conducted by Hryniuk and his
colleagues. They reviewed the literature describing variations
of standard chemotherapy in breast carcinoma (Hryniuk &
Bush, 1984) and ovarian carcinoma (Levin & Hryniuk,
1987). They found that the response rates reported in the
studies they analysed correlated well with the dose intensity
calculated as the quantity of drug administered per unit time
compared to the standard regimen. In their study of ovarian
cancer they found that they were unable to assess the
individual contribution of hexamethylmelamine because its
dose varied little in the studies published.
In an editorial Dembo (1987) has reviewed the work of
Hryniuk and colleagues by drawing analogies between their
work and current understanding of radiation dose effects. He
drew attention to some of the difficulties in interpreting the
regression analyses performed by Hryniuk and colleagues of
the dose intensity and response in various studies in different
centres. The approach in the present study avoids some of
these difficulties because the patients described here were all
treated in the same institution by the same physicians, cases
being near contemporaries of controls. Therefore either the
differences in dose intensity are the means by which an
individual was put at risk of relapse or the factor which
caused him or her to relapse also made it impossible to
achieve the intensity of treatment intended. As the body of
evidence grows to support the concept of dose intensity as a
determinant of therapeutic success in chemotherapy of
responsive tumours it seems more likely that the former is
the correct explanation. In order to resolve this question
formally it would be necessary to conduct a randomised
prospective trial in which dose intensity was the variable
being investigated. In patients with germ cell tumours,
however, there are serious ethical difficulties in introducing
changes which may compromise the outcome of treatment in
a curable cancer. A randomised study of patients with breast
cancer comparing dose intensities of doxorubicin of 11.7 and
23.3mgm-2 week-1 has shown that the higher intensity
produced a greater response rate, with greater duration of
responses and longer survival (Carmo-Pereira et al., 1987).
The four indices alpha to delta are describing different
characteristics of the treatment. Gamma depends almost
entirely on the actual frequency of administration of the first
four months treatment. The lack of difference between the
two groups therefore suggests that delays in treatment due to
myelosuppression were minimised. Delta includes in addition
an element due to the duration of treatment and the lack of
an observed difference suggests that decisions to cease
treatment were made consistently, or that the total duration
of treatment is not an important variable. As with the
observation of lack of variation in hexamethylmelamine dose
in carcinoma of the ovary (Levin & Hryniuk, 1987), these
indices do not comment on the importance of vincristine,
bleomycin, cyclophosphamide and actinomycin D in this
regimen. The indices alpha and beta, which contain the
drugs whose dose was varied, showed significant differences
between the two groups of patients, with those who relapsed
receiving less of the drugs. This supports the view that it is
necessary to ensure that patients receive as much of these
drugs as the protocol demands, with reductions being
avoided unless the toxicity of any drug in an individual
renders it absolutely necessary.
Relapse following POMB/ACE chemotherapy is associated
with a reduction in the intensity of administered treatment
especially with respect to cisplatinum, etoposide and metho-
trexate. This emphasises the need to maintain the intensity of
treatment when treating patients with these tumours.
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